{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:40:18Z","timestamp":1792269618367,"version":"4.4.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003484","name":"Heinrich-Heine-Universitat Dusseldorf","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Mutations in ABCC8 and KCNJ11 are associated with the most severe and diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are commonly used off-label as second-line treatment. While octreotide and lanreotide are the most established options, pasireotide\u2014a second-generation somatostatin analogue with higher affinity for somatostatin receptor subtype 5\u2014has been hypothesized to offer improved suppression of insulin secretion. We report the off-label use of subcutaneous pasireotide in an infant with severe CHI due to a homozygous ABCC8 mutation. The patient presented with severe persistent hypoglycemia despite high-dose octreotide, continuous glucagon infusion, and high carbohydrate requirement. The established next step would have been a subtotal pancreatectomy. Following detailed counseling, the parents expressed a strong preference to defer surgical intervention and to pursue further medical options. Thus, an individualized therapeutic trial with subcutaneous pasireotide was initiated at approximately 8 weeks of age as an attempt to avoid surgery. However, pasireotide at doses of up to 0.11 mg\/kg\/day administered every 4\u00a0h did not lead to substantial clinical improvement. Instead, treatment was associated with increased glycemic variability, as reflected by more frequent episodes of hypo- and hyperglycemia, ultimately requiring reintroduction of glucagon as rescue therapy. No adverse effects were observed. Due to the lack of therapeutic response, pasireotide was discontinued after 8 days and the patient underwent near-total pancreatectomy. In conclusion, intermittent pasireotide injections were not associated with clinical improvement in this infant with medically refractory CHI, and its use potentially contributed to increased glycemic variability and instability. Further studies are needed to evaluate the safety and efficacy of pasireotide in this vulnerable patient population.<\/jats:p>","DOI":"10.3389\/fendo.2026.1873953","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:27:28Z","timestamp":1787804848000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation"],"prefix":"10.3389","volume":"17","author":[{"given":"Calvin","family":"Kurz","sequence":"first","affiliation":[{"name":"Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital D\u00fcsseldorf, Heinrich-Heine-University","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Roeper","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital D\u00fcsseldorf, Heinrich-Heine-University","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Friesl","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital D\u00fcsseldorf, Heinrich-Heine-University","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertan","family":"Mayatepek","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital D\u00fcsseldorf, Heinrich-Heine-University","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meissner","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital D\u00fcsseldorf, Heinrich-Heine-University","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kummer","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital D\u00fcsseldorf, Heinrich-Heine-University","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Hoermann","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital D\u00fcsseldorf, Heinrich-Heine-University","place":["D\u00fcsseldorf, Germany"]},{"name":"Department of Neonatology and Pediatric Intensive Care, Children\u2019s Hospital University of Bonn","place":["Bonn, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Welters","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital D\u00fcsseldorf, Heinrich-Heine-University","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/dme.13823","article-title":"Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia","volume":"36","author":"Banerjee","year":"2019","journal-title":"Diabetes Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09548-7","article-title":"Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management","volume":"21","author":"G\u00fcemes","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1514916","article-title":"Large copy number variants are an important cause of congenital hyperinsulinism that should be screened for during routine testing","volume":"16","author":"Flanagan","year":"2025","journal-title":"Front Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2142010.005","article-title":"Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation","volume":"26","author":"Mooij","year":"2021","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000531766","article-title":"International guidelines for the diagnosis and management of hyperinsulinism","volume":"97","author":"De Leon","year":"2023","journal-title":"Hormone Res Paediatrics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820965068","article-title":"Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia","volume":"11","author":"Haris","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-018-0970-8","article-title":"Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism","volume":"13","author":"Welters","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-022-09710-3","article-title":"Pasireotide-a novel somatostatin receptor ligand after 20 years of use","volume":"23","author":"Bolanowski","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.860614","article-title":"Pasireotide for refractory hypoglycemia in Malignant insulinoma- case report and review of the literature","volume":"13","author":"Oziel-","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1408003","article-title":"Case report: Exceptional transmission of congenital hyperinsulinism from a focal CHI mother to her diffuse CHI dichorionic diamniotic twins","volume":"15","author":"Telehuz","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.aed.2025.04.001","article-title":"Maturity-onset diabetes of the young associated with a pathogenic ABCC8 variant: expanding the phenotypic spectrum","volume":"12","author":"Vel\u00e1squez-Hernandez","year":"2025","journal-title":"AACE Endocrinol Diabetes"},{"key":"B12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1210\/js.2018-00417","article-title":"Sirolimus: efficacy and complications in children with hyperinsulinemic hypoglycemia: A 5-year follow-up study","volume":"3","author":"G\u00fcemes","year":"2019","journal-title":"J Endocr Soc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-017-0621-5","article-title":"Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient","volume":"12","author":"Banerjee","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-232062","article-title":"Necrotising enterocolitis in a newborn infant treated with octreotide for chylous effusion: is octreotide safe","volume":"13","author":"Chandran","year":"2020","journal-title":"BMJ Case Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1873953\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:27:30Z","timestamp":1787804850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1873953\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":14,"alternative-id":["10.3389\/fendo.2026.1873953"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1873953","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1873953"}}